GPCRs revisited: New insights lead to novel drugs

Pharmaceuticals

Volumn 4, Issue 2, 2011, Pages 244-272

  Eglen, Richard M ^a   Reisine, Terry ^b  

^a PERKINELMER INC   (United States)

^b Reisine Biotechnology Consultants   (United States)

Author keywords

Allosterism; Crystal structure; DMR; Dualsteric; G protein; GPCR; NMR; Oligomerization; Pepducin; Pharmacophore

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; ADENOSINE A2A RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CELZENTRY; CHEMOKINE RECEPTOR CXCR4; CINACALCET; DOPAMINE 3 RECEPTOR; G PROTEIN COUPLED RECEPTOR; LY 2033298; MARAVIROC; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OXOTEMORINE; PEPDUCIN; PROTEIN INHIBITOR; RHODOPSIN; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; BLOOD VESSEL INJURY; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG MECHANISM; ELECTROCHEMICAL IMPEDANCE SPECTROSCOPY; HUMAN; LIGAND BINDING; NONHUMAN; OLIGOMERIZATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; THROMBOSIS;

EID: 79551587340     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4020244     Document Type: Review

References (132)

1. Eglen, R.; Bosse, R.; Reisine, T. Review: emerging concepts of guanine nucleotide binding protein coupled receptor function and implications for high throughput screening. ASSAY Drug Dev. Technol. 2007, 5, 425-451.
2. Eglen, R.; Reisine, T. New insights into GPCR function: implications for HTS. Methods Mol. Biol. 2009, 552, 1-13.
3. Kobilka, B.K.; Deupi, X. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 2007, 28, 397-406.
4. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.F.; Thian, F.S.; Kobilka, T.S.; Choi, H.-J.; Yao, X.-J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K.; GPCR engineering yields highresolution structural insights into β2-adrenergic receptor function. Science 2007, 318, 1266-1273.
5. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.F.; Thian, F.S.; Kobilka, T.S.; Choi, H.-J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; Stevens, R.C. High-resolution crystal structure of an engineered human β2- adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.
6. Rasmussen, S.G.; Choi1, H.-J.; Rosenbaum1, D.M.; Kobilka1, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.P.; Sanishvili, R.; Fischetti, R.F. et al. Crystal structure of the human β2 adrenergic G-protein coupled receptor. Nature 2007, 450, 383-387.
7. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.T.; Lane, J.R.; IJzerman, A.P.; Stevens, R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322, 1211-1217.
8. Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; Edwards, P.C.; Henderson, R.; Leslie, A.G.W.; Tate, C.G.; Schertler, G.F.X. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 2008, 454, 486-491.
9. Chien E.Y.; Liu, W.; Zhao, Q.; Katritch, V.; Han, G.W.; Hanson, M.A.; Shi, L.; Newman, A.H.; Javitch, J.A.; Cherezov, V.; Stevens, R.C. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 2010, 330, 1091-1095.
10. Wu B.; Chien, E.Y.T.; Mol, C.D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F.C. et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330, 1066-1071.
11. Scheerer, P.; Park, J.H.; Hildebrand, P.W.; Kim, Y.J.; Krau, N.; Choe, H.-W.; Hofmann, K.P.; Ernst, O.P. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455, 497-502.
12. Kolb, P.; Rosenbaum, D.; Irwin, J.; Jose J.; Kobilka, B.K.; Shoicheta, B.K. Structure-based discovery of β2-adrenergic receptor ligands. Proc. Natl Acad. Sci. USA 2009, 106, 6843-6848.
13. Ivetac, A.; McCammon, J. Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem. Biol. Drug Des. 2010, 76, 201-217.
14. Michino; Abola, E.; Brooks, C.L.; Dixon, J.S.; Moult, J.; Stevens, R.C. Community-wide assessment of GPCR structure modeling and ligand docking: GPCR Dock 2008. Nat. Rev. Drug Dis. 2009, 8, 455-463.
15. Law, S.F.; Yasuda, K.; Bell, G.I.; Reisine, T. Gia3 and Goa selectively associate with the cloned somatostatin receptor subtype SSTR2. J. Biol. Chem. 1993, 268, 10721-10727.
16. Law, S.F.; Reisine, T. Changes in the association of G protein subunits with the cloned mouse delta opioid receptor upon agonist binding, J. Pharmacol. Expt. Therap. 1997, 281, 1476-1486.
17. Hermans, E. Biochemical and pharmacological control of the multiplicity of coupling at Gprotein-coupled receptors. Pharmacol. Ther. 2003, 99, 25-44.
18. Maudsley, S.; Martin, B.; Luttrell, L. The origins of diversity and specificity in G protein-coupled receptor signaling. J. Pharmacol. Exp. Ther. 2005, 314, 485-494.
19. Baker, J.; Hill, S. Multiple GPCR conformations and signaling pathways: implications for antagonist affinity estimates. Trends Pharmacol. Sci. 2007, 28, 374-381.
20. Magocsi, M.; Vizi, E.; Selmeczy, Z.; Brozik, A.; Szelenyi, J. Multiple G-protein-coupling specificity of β-adrenoceptor in Macrophages. Immunology 2007, 122, 503-513.
21. Seifert R.; Dove, S. Functional selectivity of GPCR ligand stereoisomers: new pharmacological opportunities. Mol. Pharmacol 2009, 75, 13-18.
22. Gilchrist, A. Modulating G-protein-coupled receptors: from traditional pharmacology to allosterics. Trends Pharmacol. Sci. 2007, 28, 431-437.
23. Valant, C.; Gregory, K.J.; Hall, N.E.; Scammells, P.J.; Lew, M.J.; Sexton, P.M.; Christopoulos, A. A novel mechanism of G protein-coupled receptor functional selectivity. J. Biol. Chem. 2008, 283, 29312-29321.
24. Valant, C.; Sexton, P.M.; Christopoulos, A. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs. Mol. Interv. 2009, 9, 125-135.
25. Antony, J.; Kellershohn, K.; Mohr-Andrä, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S. et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 2009, 23, 442-450.
26. Mohr, K.; Tränkle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol. 2010, 159, 997-1008.
27. Kebig, A.; Kostenis, E.; Mohr, K.; Mohr-Andrä, M. An optical dynamic mass redistribution assay reveals biased signaling of dualsteric GPCR activators. J. Recep. Signal Transduct. 2009, 29, 140-145.
28. Kamal, M.; Jockers, R. Bitopic ligands: all-in-one orthosteric and allosteric. Biol. Rep. 2009, 1, 77.
29. Bouvier, M. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2001, 2, 274-286.
30. Milligan, G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 2009, 158, 5-14.
31. Albizu L. Cottet, M.; Kralikova, M.; Stoev, S.; Seyer, R.; Brabet, I.; Roux, T.; Bazin, H.; Bourrier, E.; Lamarque, L. et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 2010, 6, 587-594.
32. Hern, J.; Baig, A.; Mashanov, G.; Birdsall, B.; Corriea, J.; Lazareno, S.; Molloy, J.; Birdsall N. Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. USA 2010, 107, 2693-2698.
33. Lohse, M. Dimerization in GPCR mobility and signaling. Curr. Opin. Pharmacol. 2010, 10, 53-58.
34. Rozenfeld, R.; Devi, L. Receptor heteromerization and drug Discovery. Trends Pharmacol. Sci. 2010, 31, 124-130.
35. Hubbard, R. Structure-based drug discovery and protein targets in the CNS. Neuropharmacology 2011, 60, 7-23.
36. Schertler, G.F.; Villa, C.; Henderson, R. Projection structure of rhodopsin. Nature 1993, 362, 770-772.
37. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Trong, I.L.; Teller, D.C.; Okada, T.; Stenkamp, R.E. et al. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289, 739-745.
38. Okada, T.; Palczewski, K. Crystal structure of rhodopsin: Implications for vision and beyond. Curr. Opin. Struct. Biol. 2001, 11, 420-426.
39. Li, J.; Edwards, P.C; Burghammer, M.; Villa C.; Schertler G.F. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 2004, 343, 1409-1438.
40. Park, J.H.; Scheerer, P.; Hofmann, K.: Choe, H. Ernst, O. Crystal structure of the ligand-free Gprotein coupled receptor opsin. Nature 2008, 454, 183-187.
41. Rosenbaum, D; Rasmussen, S.; Kobilka, B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459, 356-363.
42. Kolb, P.; Rosenbaum, D.; Irwin, J.; Fung, J.; Kobilka, B.K.; Shoicheta, B. Structure-based discovery of β2-adrenergic receptor ligands. Proc. Natl. Acad. Sci. USA 2009, 106, 6843-6848.
43. Bokoch, M.; Zou, Y.; Rasmussen, S.G.F.; Liu, C.W.; Nygaard, R.; Rosenbaum, D.M.; Fung, J.J.; Choi, H.-J.; Thian, F.S.; Kobilka, T.S. et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463, 108-112.
44. Gautier, A.; Mott, H.; Bostock, M.; Kirkpatrick, J.; Nietlispach, N. Structure determination of the seven-helix transmembrane receptor sensory rhodopsin II by solution NMR spectroscopy. Nat. Struct. Mol. Biol. 2010, 17, 768-774.
45. Taylor, C.; Rockweiler, N.; Liu, C.; Rikimaru, L.; Tunemalm, A.K.; Kisselev, O.; Marshall, G. Using ligand-based virtual screening to allosterically stabilize the activated state of a GPCR. Chem. Biol. Drug Des. 2010, 75, 325-332.
46. Paterlini, G. The function of the extracellular regions in opioid receptor binding: Insights from computational biology. Curr. Top. Med. Chem. 2005, 5, 357-367.
47. Reisine, T.; Bell, G.I. Molecular biology of opiate receptors. Trends Neurosci. 1993, 16, 506-510.
48. Reisine, T.; Brownstein, M. Opioid and cannabinoid receptors. Curr. Opin. Neurobiol. 1994, 4, 406-412.
49. Reisine, T.; Pasternak, G. Opioid analgesics and antagonists. In Goodman and Gilman's: The Pharmacological Basis of Therapeutics, 9th ed.; Limbird, L., Hardman, J., Eds; Pergamon Press: McGraw-Hill, New York, 1996; pp, 521-555.
50. Wang, J.B.; Johnson, P.S.; Wu, J.M.; Wang, W.F.; Uhl, G.R. Human kappa opiate receptor second extracellular loop elevates dynorphin's affinity for human mu/kappa chimeras. J. Biol. Chem. 1994, 269, 25966-25969.
51. Meng, F.; Hoversten, M.T.; Thompson, R.C.; Taylor, L.; Watson, S.J.; Akil, H. A chimeric study of the molecular basis of affinity and selectivity of the kappa and the delta opioid receptors. Potential role of extracellular domains. J. Biol. Chem. 1995, 270, 12730-12736.
52. DeHaven, R.N.; Mansson, E.; Daubert, J.D.; Cassel, J.A. Pharmacological characterization of human kappa/mu opioid receptor chimeras that retain high affinity for dynorphin A. Curr. Top. Med. Chem. 2005, 5, 303-313.
53. Zhang, L.; DeHaven, R.N.; Goodman, M. NMR and modeling studies of a synthetic extracellular loop II of the kappa opioid receptor in a DPC micelle. Biochemistry 2002, 41, 61-68.
54. Paterlini, G.; Portoghese, P.; Ferguson, D. Molecular simulation of dynorphin A-(1-10) binding to extracellular loop 2 of the kappa-opioid receptor. A model for receptor activation. J. Med. Chem. 1997, 40, 3254-3262.
55. Valiquette, M.; Vu, H.K.; Yue, S.Y.; Wahlestedt, C.; Walker, P. Involvement of Trp-284, Val-296, and Val-297 of the human delta opioid receptor in binding of delta-selective ligands. J. Biol. Chem. 1996, 271, 18789-18796.
56. Pepin, M.C.; Yue, S.Y.; Roberts, E.; Wahlestedt, C.; Walker, P. Novel restoration of function mutagenesis strategy to identify amino acids of the delta-opioid receptor involved in ligand binding. J. Biol. Chem. 1997, 272, 9260-9267.
57. Kong, H.; Raynor, K.; Yano, H.; Takeda, J.; Bell, G. I.; Reisine, T. Agonists and antagonists bind to different domains of the cloned kappa opioid receptor. Proc. Natl. Acad. Sci. USA 1994, 91, 8042-8046.
58. Chaturvedi, K.; Shahrestanifar, M.; Howells, R.D. Mu opioid receptor, role for the amino terminus as a determinant of ligand binding affinity. Brain Res. Mol. Brain Res. 2000, 76, 64-72.
59. Decaillot, F.M.; Befort, K.; Filliol, D.; Yue, S.; Walker, P.; Kieffer, B. L. Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat. Struct. Biol. 2003, 10, 629-636.
60. Fadhil, I.; Schmidt, R.; Walpole, C.; Carpenter, K. Exploring Deltorphin II Binding to the Third Extracellular Loop of the delta-Opioid Receptor. J. Biol. Chem 2004, 279, 21069-21077.
61. Xue, J.C.; Chen, C.; Zhu, J.; Kunapuli, S.P.; de Riel, J.K.; Yu, L.; Liu-Chen, L.Y. The third extracellular loop of the mu opioid receptor is important for agonist selectivity. J. Biol. Chem. 1995, 270, 12977-12979.
62. Tikhonova, I.; Costanzi, G. Unraveling the structure and function of G protein-coupled receptors through NMR spectroscopy. Curr. Pharm. Des. 2009, 15, 4003-4016.
63. Pellegrini, M.; Mierke, D. Molecular complex of cholecystokinin-8 and N-terminus of the cholecystokinin A receptor by NMR spectroscopy. Biochemistry 1999, 38, 14775-14783.
64. Giragossian, C.; Mierke D. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin-2 receptor. Biochemistry 2002, 41, 4560-4566.
65. Giragossian, C.; Sugg, E.; Szewczyk, J.; Mierke, D. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor. J. Med. Chem. 2003, 46, 3476-3482.
66. ter Haar, E.; Koth, C.M.; Abdul-Manan, N.; Swenson, L.; Coll, J.T.; Lippke, J.A.; Lepre, C.A.; Garcia-Guzman, M.; Moore, J.M. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 2010, 18, 1083-1093.
67. Grace, C.; Perrin, M.; Gulyas, J.; Rivier, J.E.; Vale, W.W.; Riek, R. NMR structure of the first extracellular domain of corticotropin releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. J. Biol. Chem. 2010, doi/10.1074/jbc.M110.121897.
68. Grace, C.; Perrin, M.; Gulyas, J, Digruccio, M.; Cantle, J.; Rivier, J.E.; Vale, W.W.; Riek, R. Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc. Natl. Acad. Sci. USA 2007, 104, 4858-4863.
69. Pioszak, A.A.; Xu, H.E. Molecular recognition of PTH by its G protein linked receptor. Proc. Natl. Acad. Sci. USA 2008, 105, 5034-5039.
70. Parthier, C.; Kleinschmidt, M.; Neumann, P.; Rudolph, R.; Manhart, S.; Schlenzig, D.; Fanghanel, J.; Rahfeld, J.U.; Demuth, H.U.; Stubbs, M.T. Crystal structure of the incretin bound extracellular domain of a G protein coupled receptor. Proc. Natl. Acad. Sci. USA 2007, 104, 13942-13947.
71. Runge, S.; Thogersen, H.; Madsen, K.; Lau, J.; Rudolph, R. Crystal structure of the ligand bound glucagon like peptide 1 receptor extracellular domain. J. Biol. Chem. 2008, 283, 11340-11347.
72. Rajagopal, S.; Rajagopal, K.; Lefkowitz, R.J. Teaching old receptors new tricks: biasing seventransmembrane receptors. Nat. Rev. Drug Dis. 2010, 9, 373-386.
73. Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Dis. 2009, 8, 41-54.
74. Jensen, A.A.; Bräuner-Osborne, H. Allosteric modulation of the calcium-sensing receptor. Curr. Neuropharmacol. 2007, 5, 180-186.
75. Fätkenheuer G.; Pozniak, A.L.; Johnson, M.A.; Plettenberg, A.; Staszewski, S.; Hoepelman, A.I.M.; Saag, M.S.; Goebel, F.D.; Rockstroh, J.K.; Dezube, B.J. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. 2005, 11, 1170-1172.
76. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 2005, 43, 239-271.
77. Watson, C.; Jenkinson, S.; Kazmierski, W.; Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 2005, 67, 1268-1282.
78. Muniz-Medina, V.M.; Jones, S.; Maglich, J.M.; Galardi, C.; Hollingsworth, R.E.; Kazmierski, W.M.; Ferris, R.G.; Edelstein, M.P.; Chiswell, K.E.; Kenakin, T.P. The relative activity of function sparing HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol. Pharmacol. 2009, 75, 490-501.
79. Chan, W.Y.; McKinzie, D.L.; Bose, S.; Mitchell, S.N.; Witkin, J.M.; Thompson, R.C.; Christopoulos, A.; Lazareno, S.; Birdsall, N.J.; Bymaster, F.P.; Felder, C.C. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. USA 2008, 105, 10978-10983.
80. Nawaratne, V.; Leach, K.; Felder, C.C.; Sexton, P.M.; Christopoulos, A. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. J. Biol. Chem. 2010, 285, 19012-19021.
81. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000, 407, 971-977.
82. Pagano, A.; Rüegg, D.; Litschig, S.; Stoehr, N.; Stierlin, C.; Heinrich, M.; Floersheim, P.; Prezèau, L.; Carroll, F.; Pin, J.-P. et al. The non-competitive antagonists 2-methyl-6- (phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 2000, 275, 33750-33758.
83. Carroll, F.Y.; Stolle, A.; Beart, P.M.; Voerste, A.; Brabet, I.; Mauler, F.; Joly, C.; Antonicek, H.; Bockaert, J.; Müller, T. et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. 2001, 59, 965-973.
84. Chen, Y.; Nong, Y.; Goudet, C.; Hemstapat, K.; de Paulis, T.; Pin, J.P.; Conn, P.J. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 2007, 71, 1389-1398.
85. Chen, Y.; Goudet, C.; Pin, J.P.; Conn, P.J. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 2008, 73, 909-918.
86. Berry-Kravis, E.; Hessl, D.; Coffey, S.; Hervey, C.; Schneider, A.; Yuhas, J.; Hutchison, J.; Snape, M.; Tranfaglia, M.; Nguyen, D.V.; Hagerman, R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009, 46, 266-271.
87. Lee, P.H.; Gao, A.; van Staden, C.; Ly, J.; Salon, J.; Xu, A.; Fang, Y.; Verkleeren, R. Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors. Assay Drug Dev. Technol. 2008, 6, 83-94.
88. Fang, Y.; Li, G.; Ferrie, A.M. Non-invasive optical biosensor for assaying endogenous G proteincoupled receptors in adherent cells. J. Pharmacol. Toxicol. Methods 2007, 55, 314-322.
89. Schröder, R.; Janssen, N.; Schmidt, J.; Kebig, A.; Merten, N.; Hennen, S.; Müller, A.; Blättermann, S.; Mohr-Andrä, M.; Zahn, S. et al. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat. Biotechnol. 2010, 28, 943-949.
90. Wang, J.; Gilchrist, A.; Stern, P.H. Antagonist minigenes identify genes regulated by parathyroid hormone through G protein-selective and G protein co-regulated mechanisms in osteoblastic cells. Cell Signal. 2010, 23, 380-388.
91. Gilchrist, A.; Li, A.; Hamm, H.E. G alpha COOH-terminal minigene vectors dissect heterotrimeric G protein signaling. Sci. STKE 2002, 2002, l1.
92. Miller, J.; Agarwal, A.; Devi, L.; Fontanini, K.: Hamilton, J.; Pin, J.; Shields, D.; Spek, A.; Sakmar, T.; Kuliopulos, A.; Hunt, III, S. Insider access: pepducin symposium explores a new approach to GPCR modulation. Ann. NY Acad. Sci. 2009, 1180, E1-E12.
93. Tchernychev, B.; Rena, Y.; Sachdev, P.; Janz, J.M.; Haggis, L.; O'Sheaa, A.; McBride, E.; Looby, R.; Deng, Q.; McMurry, T. et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc. Natl. Acad. Sci. USA 2010, 107, 22255-22259.
94. Tressel, S.; Koukos, G.; Tchernychev, B.; Jacques, S.; Covic, L.; Kuliopulos, A. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Meth. Mol. B. 2011, 683, 259-275.
95. Swift, S., Leger, A.; Talavera, J.; Bohm, A.; Kuliopulo, A. Role of the PAR1 receptor 8th helix in signaling: the 7-8-1 receptor activation mechanism. J. Biol. Chem. 2006, 281, 4109-4116.
96. Leger, A.J.; Jacques, S.; Badar, J.; Kaneider, N.C.; Derian, C.K.; Andrade-Gordon, P.; Covic, L.; Kuliopulos, A. Blocking the protease-activated receptor 1-4 heterodimer in platelet mediated thrombosis. Circulation 2006, 113, 1244-1245.
97. Covic, L.; Misra, M.; Badar, J.; Singh, C.; Kuliopulos, A. Pepducin based intervention of thrombin-receptor signaling and systemic platelet activation. Nat. Med. 2002, 8, 1161-1165.
98. Covic, L.; Tchernychev, B.; Jacques S.; Kuliopulos, A. Pharmacology and in vivo efficacy of pepducins in hemostasis and arterial thrombosis. In Handbook of Cell-Penetrating Peptides; Taylor & Francis: NY, USA, 2007; pp. 245-257.
99. Trivedi, V.; Boire, A.; Tchernychev, B.; Kaneider, N.C.; Leger, A.J.; O'Callaghan, K.; Covic, L.; Kuliopulos, A. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009, 137, 332-343.
100. Kaneider, N.C., A.J. Leger, A. Agarwal, Nguyen, N.; Perides, G.; Derian, C.; Covic, L.; Kuliopulos, A. Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat. Immunol. 2007, 8, 1303-1312.
101. Yang, E.; Boire, A.; Agarwal, A.; Nguyen, N.; O'Callaghan, K.; Tu, P.; Kuliopulos, A.; Covic, L. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt-survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 2009, 69, 6223-6231.
102. Agarwal, A.; Covic, L.; Sevigny, L.; Kaneider, N.; Lazarides, K.; Azabdaftari, G.; Sharifi, S.; Kuliopulos, A. Targeting a metalloprotease-PAR1 signaling system with cell- penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol. Cancer Ther. 2008, 7, 2746-2757.
103. Chung, D.; Zuiderweg, E.; Fowler, C.; Soyer, O.; Mosberg, H.; Neubig, R.R. NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix. Biochemistry 2002, 41, 3596-3604.
104. Déméné, H.; Granier, S.; Muller, D.; Guillon, G.; Dufour, M.-N.; Delsuc, M.-A.; Hibert, M.; Pascal, R.; Mendre, C. Active peptidic mimics of the second intracellular loop of the V(1A) vasopressin receptor are structurally related to the second intracellular rhodopsin loop: a combined 1H NMR and biochemical study. Biochemistry 2003, 42, 8204-8213.
105. Shan, J, Weinstein, H, Mehler, E. Probing the structural determinants for the function of intracellular loop 2 in structurally cognate G-protein-coupled receptors. Biochemistry 2010, 49, 10691-10701.
106. Khelashvili, G.; Dorff, K.; Shan, J.; Camacho-Artacho, M.; Skrabanek, L.; Vroling, B.; Bouvier, M.; Devi, L.A.; George, S.R.; Javitch, J.A. et al. GPCR-OKB: the G protein coupled receptor oligomer knowledge base. Bioinformatics Appl. Note 2010, 26, 1804-1805.
107. Hipser, C.; Bushlin, I.; Gupta, A.; Gomes, I.; Devi, L. Role of antibodies in developing drugs that target G-protein-coupled receptor dimers. Mount Sinai J. Med. 2010, 77, 374-380.
108. Canals, M.; Burgueño, J.; Marcellino, D.; Cabello, N.; Canela, E.I.; Mallol, J.; Agnati, L.; Ferré, S.; Bouvier, M.; Fuxe, K. et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 2003, 278, 46741-46749.
109. McVey, M.; Ramsay, D.; Kellett, E.; Rees, S.; Wilson, S.; Pope, A.J. Milligan, G. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J. Biol. Chem. 2001, 276, 14092-14099.
110. Ciruela, F. Fluorescence-based methods in the study of protein-protein interactions in living cells. Curr. Opin. Biotechnol. 2008, 19, 338-343.
111. Mercier, J.F.; Salahpour, A.; Angers, S.; Breit, A.; Bouvier, M. Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J. Biol. Chem. 2002, 277, 44925-44931.
112. Bouvier, M.; Heveker, N.; Jockers, R.; Marullo, S.; Milligan, G. BRET analysis of GPCR oligomerization: newer does not mean better. Nat. Methods 2007, 4, 3-4.
113. Vidi, P.; Przybyla, J.; Hu, C.; Watts, V. Visualization of G protein-coupled receptor (GPCR) interactions in living cells using bimolecular fluorescence complementation (BiFC). Curr. Protoc. Neurosci. 2010, 5, 1-15.
114. Vidi, P.A.; Watts, V.J. Fluorescent and bioluminescent protein-fragment complementation assays in the study of G protein-coupled receptor oligomerization and signaling. Mol. Pharmacol. 2009, 375, 733-739.
115. Vidi, P.; Ejendalb, K.; Przybylab, J.; Watts, V. Fluorescent protein complementation assays: new tools to study G protein-coupled receptor oligomerization and GPCR-mediated signaling. Mol. Cell. Endocrinol. 2010, 331, 185-193.
116. Zheng, Y.; Akgün, E.; Harikumar, K.; Hopson, J.; Powers, M.; Lunzer, M.; Miller, L.; Portoghese, P.S. Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. J. Med. Chem. 2009, 52, 247-258.
117. Harikumar, K.; Akgun, E.; Portoghese, P.S.; Miller, L. Modulation of cell surface expression of non-activated cholecystokinin receptors using bivalent ligand-induced internalization. J. Med. Chem. 2010, 53, 2836-2842.
118. Birdsall, N. Class A GPCR heterodimers: evidence from binding studies. Trends Pharmacol. Sci. 2010, 31, 499-508.
119. Waldhoer, M.; Fong, J.; Jones, R.M.; Lunzer, M.M.; Sharma, S.K.; Kostenis, E.; Portoghese, P.S.; Whistler, J.L. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. USA 2005, 102, 9050-9055.
120. Zhang, Z.J.; Jiang, X.-L.; Zhang, S.E.; Hough, C.J.; Li, H.; Chen, J.-G.; Zhen, X.-C. The paradoxical effects of SKF83959, a novel dopamine D1-like receptor agonist, in the rat acoustic startle reflex paradigm. Neurosci. Lett. 2005, 382, 134-138.
121. Carrillo, J.J.; Pediani, J.; Milligan G. Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J. Biol. Chem. 2005, 278, 42578-42587.
122. Milligan, G.; Bouvier, M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J. 2005, 272, 2914-2925.
123. Ambrosio, M.; Zürn, A.; Lohse, M. Sensing G protein-coupled receptor activation. Neuropharmacology 2011, 60, 45-51.
124. Ziegler, N.; Bätz, J.; Zabel, U.; Lohse, M.; Hoffmann, C. FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors. Bioorg. Med. Chem. 2010, doi:10.1016/j.bmc.2010.07.060.
125. Verdonk, E.; Johnson, K.; McGuinness, R. Cellular dielectric spectroscopy: a label-free comprehensive platform for functional evaluation of endogenous receptors. Assay Drug Dev. Technol. 2006, 4, 609-619.
126. Peters, M.; Knappenberger, K.S.; Wilkins, D.; Sygowski, L.A.; Lazor, L.A.; Liu, J.; Scott, C.W. Evaluation of cellular dielectric spectroscopy, a whole-cell, label-free technology for drug discovery on Gi-coupled GPCRs. J. Biomol. Screen. 2007, 12, 312-319.
127. Peters, M.; Vaillancourt, F.; Heroux, M.; Valiquette, M.; Scott, C. Comparing Label-Free Biosensors for Pharmacological Screening With Cell-Based Functional Assays. Assay Drug Dev. Technol. 2010, 8, 219-227.
128. Hruby, V.; Tollin, G. Plasmon-waveguide resonance (PWR) spectroscopy for directly viewing rates of GPCR/G-protein interactions and quantifying affinities. Curr. Opin. Pharmacol. 2007, 7, 507-514.
129. Alves, I.; Park, C.; Hruby, V. Plasmon resonance methods in GPCR signaling and other membrane events. Curr. Protein Pept. Sci. 2005, 6, 293-312.
130. Eglen, R.; Reisine, T. Primary cells and stem cells in drug discovery: Emerging tools for highthroughput screening. Assay Drug Dev. Technol. 2010, doi:10.1089/adt.2010.0305.
131. Peterson, A.W.; Halter, M.; Tona, A.; Bhadriraju, K.; Plant, A.L. Surface plasmon resonance imaging of cells and surface-associated fibronectin. BMC Cell Biol. 2009, 26, 10-16.
132. Jun, Y.; Sheikholeslami, S.; Hostetter, D.; Tajon, C.; Craik, C.; Alivisatos, A. Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level. Proc. Natl. Acad. Sci. USA 2009, 106, 17735-17740.